Dr Reddy's, Sun, Lupin get nod to launch schizophrenia drug

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Dr Reddy's Laboratories has launched a generic version of anti-psychotic drug Quetiapine Fumarate tablets in the US market following an approval by US Food and Drugs Administration (FDA).

Separately, Sun Pharmaceutical Industries and Lupin said they too received US FDA approval to launch a generic version of the drug in that market.

Dr Reddy's shares rose post the announcement and at 13:00 hrs were up 2.2% at Rs 1,717..85 on NSE on Wednesday. Lupin gained 0.6% at Rs 515.50 and Sun Pharma was down 0.7% at Rs 572.25.

Quetiapine Fumarate tablets are a copy of AstraZeneca UK's blockbuster Seroquel tablets used for the treatment of schizophrenia and bipolar disorder.

The Seroquel brand had sales of about USD 4.6 billion in the US market for year ended December 2011, Dr Reddy's said citing IMS Health data.

AstraZeneca had said on Monday that a US court had dismissed the company's bid to extend its patent on Seroquel.